Elekta (EKTAY) Stock Price, News & Analysis

Company Overview

Elekta AB is a Sweden-based medical technology company that develops and supplies equipment, software and related services for radiation oncology and neurosurgery. Its technologies are used by hospitals and cancer treatment centers to plan and deliver precision radiation treatments for patients with cancer and neurological disorders.

The company’s portfolio includes linear accelerators, stereotactic radiosurgery systems, brachytherapy solutions, treatment-planning and oncology information software, and magnetic resonance-guided radiation therapy technology. Its products include the Leksell Gamma Knife platform, Versa HD and Harmony linear accelerators, Elekta Unity MR-linac systems, and MOSAIQ oncology software.

Elekta was founded in 1972 by Swedish neurosurgeon and inventor Lars Leksell. The company serves healthcare providers internationally, with operations, customers and service activities across Europe, the Americas, Asia and other global markets. Gustaf Salford serves as Elekta’s president and chief executive officer.

Key Stats

• Today's Range: $5.13 to $5.13
• 50-Day Range: $4.77 to $5.89
• 52-Week Range: $4.35 to $6.93
• Volume: 2,634 shs
• Average Volume: 1,218 shs
• Market Capitalization: $1.89 billion
• P/E Ratio: N/A
• Dividend Yield: 2.34%
• Price Target: N/A
• Consensus Rating: Hold

Elekta Stock Analysis - MarketRank™

Elekta scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Elekta has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Elekta has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 9.30%

Earnings Growth

Earnings for Elekta are expected to grow by 9.30% in the coming year, from $0.43 to $0.47 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elekta is -42.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elekta is -42.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Elekta has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Elekta has been sold short.

Short Interest Ratio / Days to Cover

Elekta has a short interest ratio ("days to cover") of 2.04, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elekta has recently decreased by 3.69%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Elekta pays a meaningful dividend of 2.37%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Elekta does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Elekta will have a dividend payout ratio of 25.53% next year. This indicates that Elekta will be able to sustain or increase its dividend.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.04

News Sentiment

Elekta has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Elekta this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elekta insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.28% of the stock of Elekta is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Elekta has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/27/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/25/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: OTCMKTS:EKTAY
• CIK: 1451160
• Web: www.elekta.com
• Phone: (685) 872-5400
• Fax: 46-8-587-255-00
• Employees: 4,556
• Year Founded: 1972

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 11.93
• P/E Growth: N/A
• Net Income: -$55.38 million
• Net Margins: -2.38%
• Pretax Margin: 0.40%
• Return on Equity: 13.47%
• Return on Assets: 3.84%

Debt

• Debt-to-Equity Ratio: 0.45
• Current Ratio: 0.86
• Quick Ratio: 0.62

Sales & Book Value

• Annual Sales: $1.78 billion
• Price / Sales: 1.06
• Cash Flow: $0.62 per share
• Price / Cash Flow: 8.31
• Book Value: $2.17 per share
• Price / Book: 2.36

Miscellaneous

• Outstanding Shares: 368,590,000
• Free Float: 216,435,000
• Market Cap: $1.89 billion
• Optionable: Not Optionable
• Beta: 1.03